Home / Precision Medicine (page 4)

Precision Medicine

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment …

Read More »

Otsuka to Expand its Pipeline of Antibody-Based Therapies through its $430 Million Acquisition of Visterra

TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction. …

Read More »

Discovery of New Biomarker Could Provide Personalized Treatment Options for Bladder Cancer

A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report. The cancer, called p53-like bladder cancer, is named after an active gene signature it is associated with. It is often particularly aggressive, though individual prognoses can vary quite a bit. …

Read More »

Catabasis Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in DMD

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental driver of disease progression in DMD. These results add …

Read More »

Pancreatic Cancer Patients with BRCA Mutation may Benefit from Targeted Drug

A physician-scientist at the University of Arizona Cancer Center investigated a novel treatment for pancreatic cancer patients whose tumors exhibited a harmful genetic mutation. The results, in which a type of drug called a PARP inhibitor showed early promise in treating pancreatic cancer in patients with mutations in the BRCA …

Read More »

Centogene Partners with the Universities of Greifswald and Rostock to Develop Fast-Tracked Diagnostic Workflow for Personalized Therapies for Colon and Pancreatic Tumors

ROSTOCK, Germany–(BUSINESS WIRE)–CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and accelerate treatments for rare diseases, today announced partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development of diagnostic tools for …

Read More »

Array Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with Braf-Mutant Advanced Melanoma

BOULDER, Colo., June 4, 2018 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as …

Read More »

Halozyme Identifies Plasma Biomarkers as Potential Predictors of Survival in Pancreatic Cancer

SAN DIEGO, June 1, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology (ASCO) annual meeting, …

Read More »

Castle Biosciences Launches Next-Generation Sequencing Test DecisionDx-CMSeq for Cutaneous Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-CMSeq test that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to cutaneous (skin) melanoma (CM). The DecisionDx-CMSeq NGS test will provide additional information to …

Read More »

Ovarian Cancer Drug Shows Promise in Pancreatic Cancer Patients with BRCA Mutation

PHILADELPHIA – A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers led by the Perelman School of Medicine and the Basser Center …

Read More »